Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai Xiao Fang Pharmaceutical Co EV-to-FCF?
Shanghai Xiao Fang Pharmaceutical CoSHSE:603207 +1.72%38 EV-to-FCF is 40.03 as of Jul. 27, 2026, which is 12% above its 10-year median of 35.76. GuruFocus rates SHSE:603207 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 568 Drug Manufacturers companies, Shanghai Xiao Fang Pharmaceutical Co ranks worse than 69.72% on this metric.
SHSE:603207'
s EV-to-FCF Range Over the Past 10 Years
Min: 11.9 Med: 35.76 Max: 54.13
Current: 40.03
During the past 7 years, the highest EV-to-FCF of Shanghai Xiao Fang Pharmaceutical Co was 54.13. The lowest was 11.90. And the median was 35.76.
SHSE:603207's EV-to-FCF is ranked worse than 69.72% of 568
companies
in the Drug Manufacturers industry
Industry Median: 20.585
vs SHSE:603207: 40.03
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Xiao Fang Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Shanghai Xiao Fang Pharmaceutical Co's share price for today is ¥21.87.
Shanghai Xiao Fang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.260.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shanghai Xiao Fang Pharmaceutical Co EV-to-FCF Related Terms
Shanghai Xiao Fang Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Xiao Fang Pharmaceutical Co EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Xiao Fang Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Xiao Fang Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Xiao Fang Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shanghai Xiao Fang Pharmaceutical Co's EV-to-FCF falls into.
Shanghai Xiao Fang Pharmaceutical Co's current Enterprise Value is ¥2,826.9 Mil.
Shanghai Xiao Fang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥70.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) has a EV-to-FCF of 40.03 as of Jul. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Xiao Fang Pharmaceutical Co and its competitors. This is 12% above median its historical median of 35.76. Over the past decade, Shanghai Xiao Fang Pharmaceutical Co's EV-to-FCF has ranged from 11.90 to 54.13. According to the industry distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #396 out of 568 companies in the Drug Manufacturers industry, placing it in the top 69.7%.
Is Shanghai Xiao Fang Pharmaceutical Co's EV-to-FCF too high?
Shanghai Xiao Fang Pharmaceutical Co's current EV-to-FCF of 40.03 is 12% above median its 10-year median of 35.76. Over the past 10 years, this metric has ranged from a low of 11.90 to a high of 54.13. The Drug Manufacturers industry median EV-to-FCF is 20.59. Shanghai Xiao Fang Pharmaceutical Co's value of 40.03 is 94.5% above this industry median. Based on the distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #396 out of 568 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shanghai Xiao Fang Pharmaceutical Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Xiao Fang Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Xiao Fang Pharmaceutical Co ranks #396 out of 568 companies for EV-to-FCF. This places Shanghai Xiao Fang Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 20.59. Shanghai Xiao Fang Pharmaceutical Co's value of 40.03 is 94.5% above this benchmark. Historically, Shanghai Xiao Fang Pharmaceutical Co's own EV-to-FCF has ranged from 11.90 to 54.13 over the past decade. While the company's 10-year median is 35.76 vs. the industry median of 20.59, Shanghai Xiao Fang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.59, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Xiao Fang Pharmaceutical Co's current EV-to-FCF of 40.03 is 94.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shanghai Xiao Fang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Xiao Fang Pharmaceutical Co's current EV-to-FCF is 40.03, which is 12% above median its own 10-year median of 35.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Xiao Fang Pharmaceutical Co stock overvalued right now?
Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207) has a current EV-to-FCF of 40.03. The current EV-to-FCF is 40.03, which is 12% above median its 10-year median of 35.76 and 94.5% above the Drug Manufacturers industry median of 20.59. Shanghai Xiao Fang Pharmaceutical Co's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shanghai Xiao Fang Pharmaceutical Co (SHSE:603207), the current EV-to-FCF is 40.03 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shanghai Xiao Fang Pharmaceutical Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603207 has been successfully added to your 
